EUCTR2016-002391-27-DE进行中（未招募）1 期
Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 506
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Able to comprehend and willing to sign an informed consent form.
- •2. Male and female subjects aged 30 years or older.
- •3. Diagnosed with idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria.
- •4. Disease severity Stages I-IV (modified Hoehn &Yahr staging) at ON.
- •5. Treated with three to seven daily doses of L-dopa/DDCI or L-dopa/DDCI/entacapone, which can include a slow-release formulation.
- •6. Signs of wearing-off” phenomenon according to the 9-Symptom Wearing-off Questionnaire (WOQ-9), despite optimal anti-PD therapy (based on the investigator’s judgement). The wearing-off phenomenon has to be confirmed clinically by the investigator.
- •7. For females: Postmenopausal for at least two years or surgically sterile for at least six months before screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 400
排除标准
- •1. Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome).
- •2. Severe OFF periods. Patients with rare and/or short unpredictable OFF periods are eligible.
- •3. Previous or current use of tolcapone and/or OPC.
- •4. Treatment with monoamine oxidase MAO-A and MAO-B inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day or safinamide up to 100 mg/day) within the month before screening.
- •5. Concomitant treatment with entacapone.
- •6. Use of any other investigational medicinal product (IMP), currently or within the three months (or within five half-lives of the IMP, whichever is longer) before screening..
- •7. Any medical condition that might place the subject at increased risk or interfere with assessments.
- •8. Past (within the past year) or present history of suicidal ideation or suicide attempts.
- •9. Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine.
- •10. Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
- •11. Known hypersensitivity to the ingredients of IMP (including lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption).
- •12. History of neuroleptic malignant syndrome (NMS) or non-traumatic rhabdomyolysis.
- •13. Severe hepatic impairment (Child-Pugh Class C).
- •14. For females: Breastfeeding.
- •15. Employees of the investigator, trial centre, sponsor, clinical research organisation and trial consultants, when employees are directly involved in the trial or other studies under the direction of this investigator or trial centre, and their family members.
研究者
相似试验
已完成
4 期
Efficacy and Safety of Opicapone in Clinical PracticeParkinson's Disease With Wearing-off Motor FluctuationsNCT02847442Bial - Portela C S.A.518
已完成
4 期
OpiCapone Effect on Motor Fluctuations and pAiNParkinson DiseaseNCT04986982Bial - Portela C S.A.144
已完成
不适用
Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseParkinson DiseaseNCT03959540Bial - Portela C S.A.39
尚未招募
不适用
Safety and efficacy on glaucoma treatment with 3 topical medicationsin one bottle x medications in separated bottlesopen angle glaucomaRBR-6kkmskkcentro oftalmologico de minas gerais
进行中（未招募）
不适用
Safety amd tolerability of ocaperidone in the continuation treatment of patients with schizophrenia: a double-blind, parallel group, multicentre, fixed dose, follow-up studyThe population of the study will be:- schizophrenic patients according to DSM IV-TR diagnosis- have to present the first symptoms of the schizophrenia for at least one year- have to present an exacerbation of the disease or biological/ ECG abnormality which might create a risk for the patient, obscure the effects of study treatment or interfere with drug absorption, metabolism or excretionEUCTR2004-003776-10-LVeuro3d20